

**A Bacteriophage-based Validation of a Personal Protective Equipment
Doffing Procedure to be Used with High Consequence Pathogens**

Running Title: A Bacteriophage-based Validation of PPE

Brandon A. Berryhill (BS)^{1,2, †*}, Kylie B. Burke (BS)^{1,3, †}, Andrew P. Smith (BA)^{1, †}, Jill S. Morgan (BSN)⁴, Jessica Tarabay (MPH)⁴, Josia Mamora (BSN)⁴, Jay B. Varkey (MD)³⁻⁴, Joel M. Mumma (PhD)³, Colleen S. Kraft (MD)^{3,4,5}

¹ Department of Biology, Emory University; Atlanta, Georgia, 30322, USA.

² Program in Microbiology and Molecular Genetics (MMG), Graduate Division of Biological and Biomedical Sciences (GDBBS), Laney Graduate School, Emory University; Atlanta, GA, 30322, USA.

³ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine; Atlanta, Georgia, 30322, USA.

⁴ Emory Healthcare, Atlanta, GA, 30322, USA.

⁵ Department of Pathology and Laboratory Medicine, Emory University School of Medicine; Atlanta, Georgia, 30322, USA.

† These authors contributed equally to this work

* Corresponding Author: Brandon A. Berryhill

Email: Brandon.Berryhill@emory.edu

Phone: (256)289-3171

Keywords: Personal protective equipment (PPE), Doffing, Infection Prevention, High Consequence Infectious Diseases (HCIDs), Bacteriophages

Word count: 2986

Abstract

1

2

3 **Objective** To determine if the high-level personal protective equipment used in
4 the treatment of high consequence infectious diseases is effective at stopping the
5 spread of pathogens to healthcare personnel (HCP) while doffing.

6 **Background** Personal protective equipment (PPE) is fundamental to the safety
7 of HCPs. HCPs treating patients with high-consequence infectious diseases use
8 several layers of PPE, forming complex protective ensembles. With high-
9 containment PPE, step-by-step procedures are often used for donning and
10 doffing to minimize contamination risk to the HCP, but these procedures are
11 rarely empirically validated and instead rely on following infection prevention best
12 practices.

13 **Methods** A doffing protocol video for a high-containment PPE ensemble was
14 evaluated to determine potential contamination pathways. These potential
15 pathways were tested using fluorescence and genetically marked
16 bacteriophages.

17 **Results** The experiments revealed existing protocols permit contamination
18 pathways allowing for transmission of bacteriophages to HCPs. Updates to the
19 doffing protocols were generated based on the discovered contamination

20 pathways. This updated doffing protocol eliminated the movement of viable
21 bacteriophages from the outside of the PPE to the skin of the HCP.

22 **Conclusions** Our results illustrate the need for quantitative, scientific
23 investigations of infection prevention practices, such as doffing PPE.

24

25

26 **INTRODUCTION**

27

28

29 To protect healthcare personnel (HCPs) caring for patients with communicable
30 diseases, protocols have been established to mitigate the risk of transmission [1].

31 Central to these protocols is personal protective equipment (PPE). The PPE
32 used to minimize exposure to high consequence infectious diseases (HCIDs),
33 such as Ebola virus disease, utilizes layers of barrier precautions including fluid-
34 resistant coveralls, impervious aprons or gowns, fluid-resistant footwear,
35 powered air-purifying respirators (PAPRs), and gloves. Protocols that outline
36 proper donning and doffing of the PPE are fundamental to mitigating self-
37 contamination for HCPs and preventing the transmission of contaminants outside
38 patient rooms [2]. However, PPE protocols are often based on manufacturer
39 recommendations of individual products and infection prevention best practices.
40 Accordingly, ensembles of PPE and their corresponding protocols usually have
41 not been empirically validated.

42

43 Previous studies have demonstrated that adherence to PPE doffing protocols is
44 challenging and variable among HCPs [2]; previous studies have quantitatively
45 examined and discovered high rates of deviations from established protocols [3].
46 Doffing protocols would optimally be safe even considering this high underlying

47 variability. Moreover, rigorous risk assessments of PPE ensembles should
48 consider this factor in evaluating PPE safety.

49

50 This study explores contamination risks of an established doffing protocol. To
51 validate this protocol's efficacy, we applied a quantitative analysis of the PPE
52 ensemble to test for self-contamination. This investigation consisted of two
53 phases: 1) examination of the original PPE ensemble and its doffing protocol with
54 fluorescence and bacteriophages; and 2) determination if an amended protocol
55 decreased self-contamination.

56

57 This study highlights the need for infection prevention protocols, such as high-
58 containment PPE doffing, to be evaluated in a quantitative, experimental fashion.
59 We present results from both phases of our investigation below.

60

61 **METHODS**

62

63

64 **Investigational Procedures**

65 *Movie analysis*

66 Doffing protocols were captured on video. Each movie was analyzed by authors
67 BAB, KBB, APS, and JSM who viewed and stopped the movie and recorded
68 comments when potential hazards were observed.

69

70 For each doffing trial, footage was taken from four camera angles using
71 camcorders (Canon, Japan, Model #HF R80) supplied by the Healthcare and
72 Human Factors Lab at Emory. Comments were made for possible contamination
73 during the Phase 1 phage trial and deviations from the protocol in the Phase 2
74 phage trial (Supplementary Table 1).

75

76 *Fluorescent testing*

77 To verify the contact we observed in the movie described above, we used a 0.5%
78 fluorescein solution (Millipore Sigma, USA, Catalogue #F6377) and Glo Germ
79 powder (Glo Germ, USA, #GGP10) to visualize contamination and identify the
80 steps where spread of contaminant may occur. To conduct this test, a trained
81 HCP donned a complete high-containment PPE ensemble and was then sprayed
82 with the fluorescein solution. The solution was sprayed to coat surfaces of the
83 PPE that may be exposed to contact with patients (patient-facing surfaces). The

84 HCP then doffed according to the protocol. Pictures were taken from multiple
85 angles to record how fluorescein transfer; ultraviolet flood lights (Onforu, China,
86 #UFLAU004102) were used to emphasize fluorescence. A separate test was
87 performed for aerosolization risk where the heavy-loading filter on top of the
88 PAPR hood was laden with Glo Germ powder. After the filter was removed,
89 pictures were taken with ultraviolet to capture results of the experiment.

90

91 *Phage testing*

92 Using a previously validated procedure [4], we sprayed with small spray bottles
93 (Bürkle, Germany, #10216-888) high densities (approximately 10^8 phages per
94 mL) of three genetically distinct λ phages on HCP volunteers to reflect densities
95 of pathogens found in patient samples (Supplementary Table 2). 2mL of λ
96 phages were sprayed onto three locations, and each site was sprayed with a
97 different variant of λ : one marked with a kanamycin resistance gene was sprayed
98 on the wrists; one marked with a chloramphenicol resistance gene was sprayed
99 on the back of the hood; and one lacking an antibiotic marker at the critical
100 triangle, described below. HCPs then doffed, after which their hands, forearms,
101 and PAPR were swabbed and scrubs were collected and tested for
102 bacteriophage presence and identification.

103

104 **Materials and Technical Methods**

105 *Strains*

106 *Escherichia coli* strain C was acquired from Marie-Agnès Petit from INRAe,
107 France. Bacteriophages λ (λ^{Temp}), λ^{Chl} , and λ^{Kan} was obtained from Maroš Pleška
108 at The Rockefeller University.

109

110 *Bacteriophage Lysate Preparation and Distribution*

111 Each type of λ phage lysate were inoculated, shaken, centrifuged, and filtered
112 per the methods in Burke et al. [4] to create high-titer lysates (PFU/mL between
113 1×10^8 and 1×10^9). These lysates were stored in spray bottles, transported, and
114 primed per the methods in Burke et al. [4]. Immediately after priming, each lysate
115 was sprayed with one pump from a distance of 10 cm onto the target sites for
116 initial contamination. The spray dried clear and were unidentifiable to the naked
117 eye. Contamination occurred no earlier than five minutes before the start of the
118 doffing.

119

120 *Bacteriophage Recovery*

121 Immediately after the doffing procedure, skin was sampled by applying a saline
122 wipe (Hygea, USA, #C22370) around the hands and a wipe around the forearms;
123 these wipes were stored in conical tubes (Corning, USA, #352070). Disposable
124 scrubs were then stored in a Whirl-Pak (Nasco, USA, #B01542). Four sites of
125 interest were swabbed with self-contained saline swabs (Hardy Diagnostic, USA,
126 #SRK35) using a progressive back-and-forth motion until the entire surface
127 appeared damp. To liberate phage from the saline wipe, the wipe was squeezed
128 to remove excess liquid and the extracted solution was tested. To recover phage

129 from the scrubs, 300mL of deionized water was added to the bags that contained
130 the scrubs and shaken vigorously to ensure scrubs were fully saturated. Excess
131 liquid was poured into a conical tube for testing. To recover phage from the
132 swabs, the saline containers were vortexed vigorously.

133

134 After bacteriophage recovery, all surfaces with possible phages were sprayed
135 with 70% ethanol (Decon Labs, USA, #2716) and wiped with Sani-Cloth
136 Disposable Wipes (Professional Disposables International, Inc., USA, #Q55172).

137

138 *Bacteriophage Identification and Quantification*

139 Phage identification was performed by PCR, using the methods and materials
140 used in Burke et al. [4]. Band sizes of 800bp were called λ^{Temp} , 1500bp called
141 λ^{Chl} , and 1900bp called λ^{Kan} . The PCR was performed with an O'Gene Ruler DNA
142 Ladder (Thermo Fisher Scientific, USA, #SM1563).

143

144 The serum resistance lipoprotein (*bor*) gene (Gene ID: 2703532, NCBI) of the λ
145 phages was amplified by PCR using the following primers designed in
146 PrimerBLAST (NCBI): Forward (*bor*RG1Fw) 5'-GCTCTGCGTGATGATGTTGC-3'
147 and Reverse (*bor*RG1Rv) 5'-GCAGAGAAGTTCCCCGTCAG-3'. Using the
148 double layer soft agar method [5] LB soft agar overlays containing 0.1 mL of a
149 turbid *E. coli* C overnight were prepared and allowed to harden. 0.01 mL of
150 serially diluted saline recovery solution was spotted on the overlay at four

151 densities. These plates were grown overnight at 37°C, and plaques were
152 enumerated the next day.

153

154 If samples were determined to be PCR positive but negative via spot testing,
155 100µL of sample were cultured with 1×10^7 CFU/mL log-phase *E. coli* C in 10mL
156 of LB broth. These cultures were grown with shaking for six hours, centrifuged,
157 and filtered through a 0.22 µm filter to generate boosted lysates. 300µL of these
158 lysates were plated on *E. coli* C lawns to determine viable bacteriophage
159 presence.

160

161 *Process Documentation (Videography and Still Photography)*

162 For the fluorescein and Glo Germ experiments, pictures were taken with an
163 iPhone under ultraviolet illumination in a dark room; footage was recorded with
164 one camcorder. During doffing trials, pictures and footage were recorded under
165 standard room lighting.

166 **RESULTS**

167

168

169 **Initial protocol analysis**

170 *Analysis of initial doffing movie*

171 The investigation of the initial protocol (detailed in Supplementary Table 3, 4, 5)
172 began with a movie analysis. Table 1 notes observations of potential sources of
173 contamination to the HCP during the doffing protocol displayed in Movie 1. Steps
174 can be correlated to the steps of the original protocol in Supplementary Table 3.

175

176 *Evaluating contamination via fluorescence testing*

177 In Figure 1 we present several pictures of testing with fluorescence that illustrate
178 the concerns raised by the movie. We note that the protocol as performed in our
179 trials, including this one, follows the written protocol and differs slightly from
180 Movie 1; Movie 2 accurately portrays the written doffing protocol. There are six
181 pairs of pictures: The left (L) panes show areas of concern, and the right (R)
182 panes show the spread of fluorescence from those events.

183

184 The fluorescein reveals the materials in the complete PPE ensemble that are
185 patient-facing. 1AL shows a complete ensemble, and 1AR shows the ensemble
186 without the apron. 1BL shows the ensemble under blacklight, and 1BR shows
187 contamination not covered by the apron. 1CL and 1CR highlight the “Critical

188 Triangle”, which includes parts of the shoulder, the side of the abdomen, and the
189 arm.

190 The movement of the fluorescein demonstrated in Figure 1 reveals how
191 contamination can move from the outside of the PPE ensemble to an
192 intermediate location, then ultimately to the HCP. These contamination pathways
193 are demonstrated in 1D, 1E, and 1F. 1DL shows how contamination may reach
194 the arm or Critical Triangle of the coveralls. From here, contamination could
195 transfer to the underside of the shroud (shown in 1DR) which could then move to
196 scrubs. 1E shows a second pathway, where contamination on a patient-facing
197 shoulder (1EL) transfers to arms when reaching up to roll up the PAPR hood,
198 with that contamination demonstrated in 1ER. 1F demonstrates how aerosolized
199 pathogens land on skin, scrubs, and footwear.

200 Using these results, three initial locations on the PPE were determined to pose a
201 high contamination risk. These locations are (i) the PAPR hood Critical Triangle,
202 located to the left and right of the apron and near shoulders, (ii) the wrist/lower
203 forearm area of the protective coverall, and (iii) the back of the PAPR hood near
204 the filter and shoulders.

205

206 *Doffing in the presence of a bacteriophage proxy*

207 To more accurately mirror pathogenic contamination, we inoculated three
208 genetically marked variants of λ on the three sites above to determine both the

209 origin and final location of each virus. Presented in Figure 2 are the results of
210 doffing performed by four HCPs with varying heights and body types and varying
211 experience in performing the protocol.

212

213 Figure 2 demonstrates that phages moved to the four locations we had
214 hypothesized could become contaminated. Moreover, we found these phages to
215 be viable and present at high densities. All four HCPs demonstrated
216 contamination.

217

218 These four HCPs were recorded from multiple angles while performing the
219 doffing procedure. We present in Table 2 behaviors noted during our analysis of
220 the movies which would increase the risk of contamination.

221 **Updated protocol analysis**

222

223 *Changes to the Protocol*

224 Our analysis and experiments of the first protocol revealed insufficiencies that led
225 to contamination of the HCP. We aimed to eliminate viable phage recovery by
226 limiting the observed contamination pathways. Accordingly, we altered the
227 protocol in both equipment and doffing steps (Movie 3; Supplementary Table 3;
228 Supplementary Table 4; Supplementary Table 5). Below is a table detailing
229 changes made to the PPE ensemble and procedure.

230

231 Six amendments were made to the protocol. Adjustments were made based
232 largely upon concerns raised by the phase one analysis, but amendments were
233 also incorporated for ease of doffing. Of the six changes, three were changes in
234 equipment; one was an additional step made for added equipment; and two were
235 reordered steps.

236

237 *Phage Testing with Updated Protocol*

238 We next evaluated the updated protocol with the phage testing described
239 previously. Nine HCPs doffed using the updated protocol. The results of these
240 doffing trials are presented in Figure 3.

241

242 Following the updated protocol, no viable phages were recovered. Phage DNA
243 was found via PCR from several locations (indicated by an X) but viable phages
244 were unable to be recovered from these PCR-positive samples even after
245 providing a bacterial host. This indicates that the phages moved during doffing,
246 but these phages were likely inactivated by the alcohol-based sanitizer during
247 hand hygiene. Even if a contamination pathway was not eliminated, the updated
248 protocol limited those pathways to contamination on gloves where sanitation
249 could deactivate the bacteriophages.

250

251 Deviations from the doffing protocol by HCPs could contribute to variability in the
252 results shown in Figure 3. We analyzed footage of each HCP doffing and noted
253 deviations from the protocol which may lead to the spread of bacteriophages
254 (Supplementary Table 1). Several HCPs deviated from the procedure. However,
255 these deviations did not increase contamination per the results in Figure 3.

256

257 **DISCUSSION**

258

259

260 PPE forms the cornerstone of safety for HCPs, but for HCPs working with HCIDs,
261 satisfactory high-containment PPE is especially important[6]. Hundreds of HCPs
262 experienced near-miss events, infections, or death from Ebola virus disease [7,
263 8]. Although individual pieces of equipment receive National Institute for
264 Occupational Safety & Health approval, PPE ensembles and their doffing
265 protocols do not. Indeed, Koh et al. wrote over twenty years ago that PPE
266 needed to be evaluated for efficacy against infection from SARS – this is a
267 problem that has needed addressal for decades [9], and later, the same call to
268 action was issued for empirical review of Ebola PPE and ensembles [10].

269

270 This PPE ensemble had not been assessed by empirical means. Our goal was to
271 evaluate the ensemble and doffing protocol for possible contamination pathways
272 and offer interventions to mitigate potential contamination. Even a slight
273 contamination of an HCID could be a threat to HCPs (Supplementary Table 2).
274 Thus, the aim of our interventions was to prevent viable self-contamination. We
275 note that although other methods exist for analyzing the antiviral and disinfection
276 qualities of PPE and its ensembles [11, 12], we elected to focus exclusively on
277 how this ensemble performed in the transfer of pathogens.

278

279 Our first phase of this study began with an examination of a movie depicting the
280 original protocol. The original protocol followed infection prevention best
281 practices and was designed with disease containment in mind, but an in-depth
282 evaluation revealed potential contamination pathways. We found from the
283 fluorescence testing that contamination moved through the pathways we had
284 hypothesized onto scrubs and skin.

285

286 Fluorescence experiments, however, carry limitations [13]. Fluorescence does
287 not reflect sanitation measures and can be visually tracked by participants.
288 Contamination experiments with phages resolve both failings. The viruses are
289 visually undetectable and can be inactivated via alcohol-based sanitation but
290 pose no appreciable risk [4, 14]. With the original doffing protocol, all participants
291 had at least one contamination with at least 1800 virions present – an amount far
292 greater than the minimum infective dose of many HCIDs (Supplementary Table
293 2).

294

295 We next offered an assortment of interventions. Modifications were made not
296 only to reduce contamination by contact, but also to make doffing easier.
297 Reducing discomfort for HCPs may reduce deviations from a protocol, reducing
298 contamination. The result of these changes manifested in the phage experiment
299 with the updated protocol. In the second phage experiment, we did not recover a
300 viable population of phage on any of the nine HCPs. Through PCR, we found
301 phage DNA in several locations, indicating that the phages were inactivated by

302 the use of alcohol-based sanitizer during the doffing. Phages that may have
303 contaminated several locations were routed through pathways that included
304 successful hand sanitation. Moreover, updates to the protocol eliminated
305 intermediate contamination locations present in the original doffing protocol,
306 which would have re-contaminated the HCP at later doffing steps. These results
307 were observed despite deviations from the protocol by the HCPs during their
308 doffings. The protocol, built to include redundancies and reduce events of
309 contamination, allowed for small deviations without self-contamination.

310

311 This study does contain limitations. The original contamination was deliberately
312 placed according to the fluorescent test with the intention of revealing
313 contamination pathways. Thus, we cannot wholly capture contamination that
314 would occur in a clinical setting – instead, we show how specific contamination
315 can be tracked and eliminated through specific procedures. Further studies are
316 needed to capture how contamination may move throughout a clinical
317 environment, on PPE and otherwise. We further note that phages are only
318 proxies. Using HCIDs for studies such as this is not ethical, but accordingly, we
319 are closely approximating how they would function in a clinical setting through
320 phages.

321

322 With the initial PPE ensemble and doffing protocol, contamination occurred that
323 would have endangered the individual HCP and the community at large had it
324 occurred with a dangerous pathogen. Through modifications of both protocol and

325 equipment, the doffing protocol was successfully improved from initially incurring
326 dangerous amounts of contamination to eliminating viable contaminants in all
327 cases. These tests did not pose a great financial burden. Excluding PPE costs,
328 each trial cost less than \$45 USD, and our interventions were modest. Based on
329 our results, validation of other healthcare PPE protocols by quantitative methods
330 such as those we employed here is both logistically feasible and informative. No
331 hospital procedure is designed for failure, but with empirical validation, those
332 procedures can ensure they provide necessary protection.

333 ***Acknowledgments***

334 We thank the other members of the Levin Lab, particularly Joshua Manuel and
335 Bruce Levin, for their advice and assistance. We also Jessica Carag and Darryl
336 Grant for their help with revising this manuscript.

337

338 ***Author Contributions:***

339 Conceptualization: CSK, JSM, BAB

340 Methodology: JBV, JM, JT, JSM, KBB, BAB

341 Investigation: JSM, APS, KBB, BAB

342 Visualization: APS, KBB, BAB

343 Funding Acquisition: CSK, JMM

344 Project Administration: CSK, JBV

345 Supervision: JSM, BAB

346 Writing – Initial Draft: CSK, JT, JSM, APS, KBB, BAB

347 Writing – Review & Editing: CSK, JMM, JBV, JM, JT, JSM, APS, KBB, BAB

348

349 ***Financial Support***

350 This work was supported by funds from the US National Institute of General
351 Medical Sciences [grant number R35GM136407 to Bruce R. Levin]; the US
352 National Institute of Allergy and Infectious Diseases [grant number
353 U19AI158080-02 to Bruce R. Levin]; and the Centers for Disease Control and
354 Prevention [grant number NU38CK000481 to Joel M. Mumma]. The funding
355 sources had no role in the design of this study and will not have any role during

356 its execution, analysis, interpretation of the data, or drafting of this report. The
357 content is solely the responsibility of the authors and do not necessarily
358 represent the official views of the Centers for Disease Control and Prevention.

359

360 ***Potential Conflicts of Interest***

361 The authors have no potential conflicts of interest to declare.

362

363 ***Data Availability***

364 All data generated for this manuscript are available in the manuscript or its
365 supplementary material.

366

367 **REFERENCES**

- 368 1. Centers for Disease Control and Prevention NCFEaZIDN, Division of Healthcare Quality
369 Promotion (DHQP). Guidance on Personal Protective Equipment (PPE) To Be Used By
370 Healthcare Workers during Management of Patients with Confirmed Ebola or Persons
371 under Investigation (PUIs) for Ebola who are Clinically Unstable or Have Bleeding,
372 Vomiting, or Diarrhea in U.S. Healthcare Settings, Including Procedures for Donning and
373 Doffing PPE. Accessed 25 April.
- 374 2. Casanova LM, Erukunuakpor K, Kraft CS, et al. Assessing Viral Transfer During Doffing of
375 Ebola-Level Personal Protective Equipment in a Biocontainment Unit. *Clin Infect Dis*
376 **2018**; 66(6): 945-9.
- 377 3. Kwon JH, Burnham CD, Reske KA, et al. Assessment of Healthcare Worker Protocol
378 Deviations and Self-Contamination During Personal Protective Equipment Donning and
379 Doffing. *Infect Control Hosp Epidemiol* **2017**; 38(9): 1077-83.
- 380 4. Burke KB, Berryhill BA, Garcia R, et al. A methodology for using Lambda phages as a
381 proxy for pathogen transmission in hospitals. *J Hosp Infect* **2023**; 133: 81-8.
- 382 5. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of
383 bacteriophages by double agar overlay plaque assay. *Methods Mol Biol* **2009**; 501: 69-
384 76.
- 385 6. MacIntyre CR, Chughtai AA, Seale H, Richards GA, Davidson PM. Uncertainty, risk
386 analysis and change for Ebola personal protective equipment guidelines. *Int J Nurs Stud*
387 **2015**; 52(5): 899-903.
- 388 7. World Health O. EBOLA RESPONSE ROADMAP SITUATION REPORT: World Health
389 Organization, **2014**.
- 390 8. Houlihan CF, McGowan CR, Dicks S, et al. Ebola exposure, illness experience, and Ebola
391 antibody prevalence in international responders to the West African Ebola epidemic
392 2014-2016: A cross-sectional study. *PLoS Med* **2017**; 14(5): e1002300.
- 393 9. Koh D, Lim MK, Chia SE. SARS: health care work can be hazardous to health. *Occup Med*
394 (Lond) **2003**; 53(4): 241-3.
- 395 10. Sprecher AG, Caluwaerts A, Draper M, et al. Personal Protective Equipment for Filovirus
396 Epidemics: A Call for Better Evidence. *J Infect Dis* **2015**; 212 Suppl 2(Suppl 2): S98-s100.
- 397 11. Xue X, Coleman CM, Duncan JD, et al. Evaluation of the relative potential for contact and
398 doffing transmission of SARS-CoV-2 by a range of personal protective equipment
399 materials. *Sci Rep* **2022**; 12(1): 16654.
- 400 12. Pfuderer L, Stark WJ, Grass RN. Synthetic Microbial Surrogates Consisting of Lipid
401 Nanoparticles Encapsulating DNA for the Validation of Surface Disinfection Procedures.
402 *ACS Applied Bio Materials* **2023**; 6(3): 1252-9.
- 403 13. Hall S, Poller B, Bailey C, et al. Use of ultraviolet-fluorescence-based simulation in
404 evaluation of personal protective equipment worn for first assessment and care of a
405 patient with suspected high-consequence infectious disease. *J Hosp Infect* **2018**; 99(2):
406 218-28.
- 407 14. Burke KB, Berryhill BA, Garcia R, et al. Using Lambda phages as a proxy for pathogen
408 transmission in hospitals. *medRxiv* **2022**: 2022.09.09.22279770.
- 409 15. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of
410 patients exposed to biological warfare agents. *Jama* **1997**; 278(5): 399-411.

- 411 16. Vetter P, Fischer WA, 2nd, Schibler M, Jacobs M, Bausch DG, Kaiser L. Ebola Virus
412 Shedding and Transmission: Review of Current Evidence. *J Infect Dis* **2016**; 214(suppl 3):
413 S177-s84.
- 414 17. Suess T, Renschmidt C, Schink SB, et al. Comparison of shedding characteristics of
415 seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007-2011.
416 *PLoS One* **2012**; 7(12): e51653.
- 417 18. Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory and Enteric
418 Viruses Transmitted Through Food and the Environment. *Food Environ Virol* **2011**; 3(1):
419 1-30.
- 420 19. Musisi E, Sessolo A, Kaswabuli S, et al. High Mycobacterium tuberculosis Bacillary Loads
421 Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential
422 Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of
423 Tuberculosis. *Microbiol Spectr* **2022**; 10(1): e0210021.
- 424 20. Sakamoto K. The Pathology of Mycobacterium tuberculosis Infection. *Veterinary*
425 *Pathology* **2012**; 49(3): 423-39.
- 426 21. SeyedAlinaghi S, Karimi A, Mojdeganlou H, et al. Minimum infective dose of severe
427 acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic
428 review. *SAGE Open Med* **2022**; 10: 20503121221115053.
- 429 22. Oh M-d, Park WB, Choe PG, et al. Viral Load Kinetics of MERS Coronavirus Infection.
430 *New England Journal of Medicine* **2016**; 375(13): 1303-5.
- 431 23. Frey SE, Newman FK, Yan L, Belshe RB. Response to Smallpox Vaccine in Persons
432 Immunized in the Distant Past. *JAMA* **2003**; 289(24): 3295-9.
- 433 24. Price PA, Jin J, Goldman WE. Pulmonary infection by *Yersinia pestis* rapidly
434 establishes a permissive environment for microbial proliferation. *Proceedings of the*
435 *National Academy of Sciences* **2012**; 109(8): 3083-8.
- 436 25. Kolodziejek AM, Hovde CJ, Minnich SA. *Yersinia pestis* Ail: multiple roles of a single
437 protein. *Front Cell Infect Microbiol* **2012**; 2: 103.

438

439

440 **TABLES**

441

442 **Table 1: Events of concern noted during annotation of the PPE doffing**
443 **movie.**

Event Description	Step Number
When removing the outer gloves, the sleeves of the coverall may come into contact with the front surface of the PAPR hood.	17
Removing the heavy-loading PAPR filter creates a high risk of aerosolization.	19
The tie at the neck of the PAPR is not fully covered by the apron and could potentially contaminate the gloves when it is broken.	21
Incidental contact to the inside of the PAPR hood may occur when reaching in to unzip the coverall.	27
When the coverall is being pulled down the PAPR hood is free to move about and may contact skin of participant.	28
When marching in place to remove coverall, incidental contact with the PAPR hood occurs.	30

When marching in place, the PAPR hood is free to move around, potentially generating aerosols.	30
When the coverall is removed from the legs, one is instructed to “keep your hands together.” Forearms came in contact with the front of the PAPR hood that is not covered by the apron (henceforth referred to as the PAPR hood Critical Triangle).	31
When disposing of the coverall, there is a risk of incidentally interacting with patient-facing surfaces should care not be taken when picking the coverall off the ground.	32*
When removing the PAPR hood, the back of the hood is pulled forward from the back of the head to cover the face shield. The corner of the PAPR hood can fold out so that the PAPR hood Critical Triangle is exposed and the HCP removing the PAPR has no way of seeing this.	37
When the PAPR hood is flipped forward, the back of the PAPR can contact the front of one’s scrubs.	38
While reaching back and grabbing the hood, there is a large amount of contact between bare forearms, scrubs, and the PAPR hood Critical Triangle.	37

When locating the edges of the visor, incidental contact with the face may occur.	38
General Procedural Notes	
The alcohol sanitation is only being performed on gloves and not the forearms or wrists.	

444 *This step in the movie deviated from the written protocol.

445

446 **Table 2: Concerns noted while reviewing movie of four HCPs doffing.**

Event Description	Step Number
When removing the heavy-loading filter, people tend to not be conscious of where it is and have a tendency to either swing it around, aerosolizing particles, or touch it to their PAPR hood.	19
During the stomping to remove the coverall, the PAPR hood moves around substantially, often coming into contact with the scrubs and in the forearms.	30

One HCP misinterpreted how they should hold their hands in front of their body when removing the coverall and put their clasped hands against the front of the PAPR hood.	31
Clasping the hands in front of the body when removing the coverall often results in the bare forearms interacting with the front and/or Critical Triangle* of the PAPR.	31
Any manipulation above the head post coverall removal puts the HCP's forearms in contact with the PAPR hood Critical Triangle.	37-39
The PAPR hood repeatedly bunches up or flips over near the shoulders.	
On short HCPs, the front of the PAPR hood folds in on itself easily.	
On particularly tall HCPs, the apron does not cover nearly as much of the coverall and PAPR as it does on shorter individuals.	

447 *Critical Triangle = The side of the PAPR hood, coveralls, and arm, which may be

448 exposed and facilitate contamination

449

450

451 **Table 3: Updates to the protocol.**

452

Protocol Amendments			
Old Protocol	New Protocol	Revision	Comment
No inner shoe liner	Calf-high shoe liner over shoes and pant legs	Add inner shoe cover	Makes doffing coverall easier
Regular length inner gloves	Extended cuff inner gloves	Change length of inner gloves	Reduces risk of exposed skin at wrist
Outer gloves donned before PAPR	Outer gloves donned last	Move step for donning outer gloves	Outer gloves are worn over sleeve of gown
Apron	Gown	Replaced apron with gown	Improved coverage of PAPR hood at shoulders and Critical Triangle

Heavy-loading filter removed after apron	Heavy-loading filter removed first	Move step for heavy-loading filter removal	Removes higher-contaminated items earlier in doffing protocol
No gown	Gown sleeves freed from outer gloves	Insert step to pull gown sleeve out of the outer glove cuff	Facilitates gown removal

453

454

455 **FIGURE LEGENDS**

456

457

458 **Figure 1: Fluorescent visualization of areas and actions of concern during**

459 **doffing.** Experimental results of doffing with fluorescent markers present for

460 specific actions of concern or highlighting areas of concern, as found during

461 review of the doffing protocol movie. **Left (L):** Before; shows areas that may be

462 of concern. **Right (R):** After; shows potential concerns by transfer of

463 fluorescence. **(A)** The original PPE ensemble in natural light, both with the apron

464 and with the apron removed. **(B)** Patient facing surfaces of the PPE not covered

465 by the apron which could become contaminated. **(C)** Critical Triangle area of the
466 PAPR. **(D)** Interaction of the coverall sleeves with the inside of the PAPR hood.
467 **(E)** Transfer of contaminate from the PAPR hood to the forearm that can occur
468 during doffing. **(F)** Aerosolization of fine powder trapped on the heavy-loading
469 filter.

470

471 **Figure 2: Phage recovery after doffing PPE.** Experimental results of doffing
472 protocols performed by four HCPs with three bacteriophages initially inoculated
473 on the PAPR Critical Triangle, coverall cuffs, and the back of the PAPR hood.
474 Numbers inside each square represents the number of PFU/mL recovered from
475 that location.

476

477 **Figure 3: Bacteriophage recovery after doffing PPE with the altered**
478 **protocols.** Experimental results of the altered doffing protocols performed by
479 nine HCPs with three bacteriophages initially inoculated on the PAPR Critical
480 Triangle, coverall cuffs, and the back of the PAPR hood. An X denotes that the
481 phage DNA from the origin location was found at that sampled location at the end
482 of doffing via PCR. To test for viable phages below the limit of detection (1×10^2
483 PFU/mL) samples were incubated with a susceptible bacteria host and no viable
484 phages were recovered from any HCP.

485

486 **MOVIE LEGENDS**

487

488

489 **Movie 1: Original Training Video.** The basis for Table 1. Slight deviations occur
490 between this video and Supplementary Table 3.

491

492 **Movie 2: Original Doffing Protocol.** A demonstration of the original doffing
493 protocol. The steps performed are detailed in Supplementary Table 3.

494

495 **Movie 3: Updated Doffing Protocol.** A demonstration of the updated doffing
496 protocol. The steps performed are detailed in Supplementary Table 3.

497